Cargando…
H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection
H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS: Patients w...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987217/ https://www.ncbi.nlm.nih.gov/pubmed/35044851 http://dx.doi.org/10.1200/JCO.21.01802 |
_version_ | 1784682692129849344 |
---|---|
author | Shen, Yu-Chuan Hsu, Hui-Ching Lin, Tzu-Min Chang, Yu-Sheng Hu, Li-Fang Chen, Lung-Fang Lin, Sheng-Hong Kuo, Pei-I. Chen, Wei-Sheng Lin, Yi-Chun Chen, Jin-Hua Liang, Yu-Chih Chang, Chi-Ching |
author_facet | Shen, Yu-Chuan Hsu, Hui-Ching Lin, Tzu-Min Chang, Yu-Sheng Hu, Li-Fang Chen, Lung-Fang Lin, Sheng-Hong Kuo, Pei-I. Chen, Wei-Sheng Lin, Yi-Chun Chen, Jin-Hua Liang, Yu-Chih Chang, Chi-Ching |
author_sort | Shen, Yu-Chuan |
collection | PubMed |
description | H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS: Patients with HBV, HCV, or dual HBV-HCV infection were enrolled from Taiwan's National Health Insurance Research Database and examined for the period from January 1, 2006, to December 31, 2015. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the association between AH use and HCC risk. RESULTS: We included patients with HBV infection (n = 521,071), HCV (n = 169,159), and dual HBV-HCV (n = 39,016). Patients with HBV, HCV, or dual virus infection who used AHs exhibited significantly lower risk of HCC relative to patients who did not use AH, with their adjusted hazard ratio being 0.489 (95% CI, 0.455 to 0.524), 0.484 (95% CI, 0.450 to 0.522), and 0.469 (95% CI, 0.416 to 0.529), respectively. Furthermore, there was a dose-response relationship between AH use and the risk of HCC in the HBV cohort. The adjusted hazard ratios were 0.597 (95% CI, 0.530 to 0.674), 0.528 (0.465 to 0.600), 0.470 (0.416 to 0.531), and 0.407 (0.362 to 0.457) for AH use of 28-42, 43-63, 64-119, and ≥ 120 cumulative defined daily doses, respectively, relative to no AH use. Additionally, there was also a dose-response relationship between AH use and the risk of HCC in the HCV and dual HBV-HCV cohorts. CONCLUSION: AH use may reduce the risk for HCC among patients with HBV, HCV, or dual infection in a dose-dependent manner. Further mechanistic research is needed. |
format | Online Article Text |
id | pubmed-8987217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-89872172022-04-07 H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection Shen, Yu-Chuan Hsu, Hui-Ching Lin, Tzu-Min Chang, Yu-Sheng Hu, Li-Fang Chen, Lung-Fang Lin, Sheng-Hong Kuo, Pei-I. Chen, Wei-Sheng Lin, Yi-Chun Chen, Jin-Hua Liang, Yu-Chih Chang, Chi-Ching J Clin Oncol ORIGINAL REPORTS H1-antihistamines (AHs) may exert protective effects against cancer. This study investigated the association of AH use with the risk of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV), hepatitis C virus (HCV), or dual HBV-HCV virus infection. MATERIALS AND METHODS: Patients with HBV, HCV, or dual HBV-HCV infection were enrolled from Taiwan's National Health Insurance Research Database and examined for the period from January 1, 2006, to December 31, 2015. We used the Kaplan-Meier method and Cox proportional hazards regression to evaluate the association between AH use and HCC risk. RESULTS: We included patients with HBV infection (n = 521,071), HCV (n = 169,159), and dual HBV-HCV (n = 39,016). Patients with HBV, HCV, or dual virus infection who used AHs exhibited significantly lower risk of HCC relative to patients who did not use AH, with their adjusted hazard ratio being 0.489 (95% CI, 0.455 to 0.524), 0.484 (95% CI, 0.450 to 0.522), and 0.469 (95% CI, 0.416 to 0.529), respectively. Furthermore, there was a dose-response relationship between AH use and the risk of HCC in the HBV cohort. The adjusted hazard ratios were 0.597 (95% CI, 0.530 to 0.674), 0.528 (0.465 to 0.600), 0.470 (0.416 to 0.531), and 0.407 (0.362 to 0.457) for AH use of 28-42, 43-63, 64-119, and ≥ 120 cumulative defined daily doses, respectively, relative to no AH use. Additionally, there was also a dose-response relationship between AH use and the risk of HCC in the HCV and dual HBV-HCV cohorts. CONCLUSION: AH use may reduce the risk for HCC among patients with HBV, HCV, or dual infection in a dose-dependent manner. Further mechanistic research is needed. Wolters Kluwer Health 2022-04-10 2022-01-19 /pmc/articles/PMC8987217/ /pubmed/35044851 http://dx.doi.org/10.1200/JCO.21.01802 Text en © 2022 by American Society of Clinical Oncology https://creativecommons.org/licenses/by-nc-nd/4.0/Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: https://creativecommons.org/licenses/by-nc-nd/4.0/ |
spellingShingle | ORIGINAL REPORTS Shen, Yu-Chuan Hsu, Hui-Ching Lin, Tzu-Min Chang, Yu-Sheng Hu, Li-Fang Chen, Lung-Fang Lin, Sheng-Hong Kuo, Pei-I. Chen, Wei-Sheng Lin, Yi-Chun Chen, Jin-Hua Liang, Yu-Chih Chang, Chi-Ching H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection |
title | H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection |
title_full | H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection |
title_fullStr | H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection |
title_full_unstemmed | H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection |
title_short | H1-Antihistamines Reduce the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus, Hepatitis C Virus, or Dual Hepatitis B Virus-Hepatitis C Virus Infection |
title_sort | h1-antihistamines reduce the risk of hepatocellular carcinoma in patients with hepatitis b virus, hepatitis c virus, or dual hepatitis b virus-hepatitis c virus infection |
topic | ORIGINAL REPORTS |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8987217/ https://www.ncbi.nlm.nih.gov/pubmed/35044851 http://dx.doi.org/10.1200/JCO.21.01802 |
work_keys_str_mv | AT shenyuchuan h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT hsuhuiching h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT lintzumin h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT changyusheng h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT hulifang h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT chenlungfang h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT linshenghong h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT kuopeii h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT chenweisheng h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT linyichun h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT chenjinhua h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT liangyuchih h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection AT changchiching h1antihistaminesreducetheriskofhepatocellularcarcinomainpatientswithhepatitisbvirushepatitiscvirusordualhepatitisbvirushepatitiscvirusinfection |